Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

3(37.5%)

Phase 2

2(25.0%)

Phase 4

2(25.0%)

Phase 1

1(12.5%)

8Total

N/A(3)

Phase 2(2)

Phase 4(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06940895Phase 2Completed

Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans

Role: lead

NCT06938815Not ApplicableCompleted

A Novel Regimen for Treatment and Prevention of Post-Inflammatory Hyperpigmentation in Skin of Color

Role: lead

NCT06952517Phase 2Recruiting

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

Role: lead

NCT04169100Phase 4Unknown

Novel Form of Acquired Long QT Syndrome

Role: lead

NCT03307447Phase 4Unknown

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

Role: lead

NCT01020851Not ApplicableCompleted

The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attack (TIA) or Stroke Trial

Role: lead

NCT01043354Not ApplicableCompleted

TACTICS (Targeting Adherence to Cholesterol-lowering Therapy to Improve Control Study)

Role: lead

NCT01105104Phase 1Unknown

An Enhanced Medication Monitoring Program

Role: collaborator

All 8 trials loaded